@article{50e0dc30ae304cfebf22d601b5216baf,
title = "Atopic dermatitis: Emerging therapies",
abstract = "Crisaborole and dupilumab represent the first 2 Food and Drug Administration (FDA)-approved therapies for atopic dermatitis (AD) in more than 15 years, and there are many promising drugs currently in development. This new wave of therapeutics capitalizes on the large body of work clarifying the pathogenesis of AD over the last several decades. In particular, type 2 cytokine-driven inflammation and skin barrier dysfunction are key processes underlying AD pathogenesis.",
author = "Eric Simpson and Jeremy Udkoff and Jenna Borok and Wynnis Tom and Lisa Beck and Eichenfield, {Lawrence F.}",
note = "Funding Information: 1Department of Dermatology, Oregon Health & Science University, Portland, Oregon. 2Division of Pediatric and Adolescent Dermatology, Rady Children{\textquoteright}s Hospital, San Diego, California. 3Departments of Dermatology and Pediatrics, University of California, San Diego School of Medicine, La Jolla, California. 4Department of Dermatology, Medicine and Pathology, University of Rochester Medical Center, Rochester, New York. *These authors contributed equally. Disclosures: Dr Simpson reports personal fees from AbbVie Inc, grants and personal fees from Anacor Pharma, Glaxo Smith Kline, Regeneron Pharmaceuticals, Inc, Eli Lilly Co; personal fees from Celgene Corporation, Dermira Pharmaceutical Co, Galderma, Genentech, Inc, Leo Pharmaceutical Co, Menlo Therapeutics, Sanofi Genzyme, Valeant Pharmaceutical Co; grants from MedImmune, Novartis, Roivant Sciences, Tioga Pharmaceuticals, Inc, Vanda Pharmaceuticals, Inc, outside the submitted work. Mr Udkoff reports personal fees from Lucid Group 3AD Bibliographic Fellowship outside the submitted work. Dr. Borok has nothing to disclose. Dr. Beck reports grants from Abbvie, personal fees from GSK, personal fees from Roche, personal fees from Janssen, personal fees from Lilly, personal fees from Novartis, grants and personal fees from Regeneron, personal fees from Sanofi, during the conduct of the study; other from Pfizer, outside the submitted work. Dr Eichenfield has received honoraria as a consultant for Allergan, Anacor/Pfizer, DS Biopharma, Galderma Labs, Genentech, Lilly, Medimetriks, Otsuka/Med-imetriks, Ralaxar, and Regeneron/Sanofi. He is an investigator for Regeneron/ Sanofi, receiving no compensation; receives equity options as a consultant for TopMD; and receives honoraria as a consultant, advisory board member, and speaker for Valeant. Dr Tom reports personal fees and other from Anacor Pharmaceuticals, Inc, other from Medimetriks. Inc, other from Regeneron, Inc, other from Incyte, Inc, outside the submitted work. Correspondence: Eric Simpson, MD, MCR, simpsone@ohsu.edu. Publisher Copyright: {\textcopyright} 2017 Frontline Medical Communications.",
year = "2017",
month = sep,
day = "1",
doi = "10.12788/j.sder.2017.0137",
language = "English (US)",
volume = "36",
pages = "124--130",
journal = "Seminars in Cutaneous Medicine and Surgery",
issn = "1085-5629",
publisher = "W.B. Saunders Ltd",
number = "3",
}